Ex Vivo Drug Sensitivity Testing and Mutation Profiling

Conditions:   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Large Cell Lymphoma;   Refractory Childhood Acute Lymphoblastic Leukemia;   Refractory Childhood Hodgkin Lymphoma;   Refractory Childhood Malignant Ger m Cell Neoplasm;   Recurrent Childhood Brain Tumor;   Recurrent Childhood Brainstem Glioma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childh ood Gliosarcoma;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive Intervention:   Sponsors:   Florida International University;   Nicklaus Children's Hospital f/k/a Miami Children's Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Could the addition of rituximab to cladribine treatment help clear minimal residual disease in patients with hairy cell leukemia?Journal of Clinical Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Brain Tumor | Cancer & Oncology | Children | Chronic Leukemia | Chronic Myeloid Leukaemia | Ependymoma | Glioma | Hospitals | Leukemia | Lymphoma | Research | Rhabdomyosarcoma | Sarcomas